Trade

Zydus Lifesciences share price

Moderate risk
  • 19%Low risk
  • 19%Moderate risk
  • 19%Balanced risk
  • 19%High risk
  • 19%Extreme risk
  • ₹917.20(0.36%)
    December 17, 2025 11:22:19 AM IST
    • NSE
    • BSE
  • Vol : 169.68 K (NSE + BSE)
    Last 20 day avg : 974.32 K

Zydus Lifesciences is trading 0.36% upper at Rs 917.20 as compared to its last closing price. Zydus Lifesciences has been trading in the price range of 920.00 & 914.75. Zydus Lifesciences has given -5.90% in this year & -0.64% in the last 5 days. Zydus Lifesciences has TTM P/E ratio 20.08 as compared to the sector P/E of 28.46.There are 28 analysts who have initiated coverage on Zydus Lifesciences. There are 4 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 5 analysts have given the stock a sell rating.The company posted a net profit of 1,258.60 Crores in its last quarter.Listed peers of Zydus Lifesciences include Divi's Laboratories (-0.34%), Dr Reddy's Laboratories (-0.24%), Torrent Pharmaceuticals (-0.50%).The Mutual Fund holding in Zydus Lifesciences was at 4.70% in 30 Sep 2025. The MF holding has decreased from the last quarter. The FII holding in Zydus Lifesciences was at 7.34% in 30 Sep 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Dec 17, 2025, 05:57 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.54
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.13
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    1.19
    Higher than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    3.87
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    18.85
    Lower than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    0.70
    Indicates undervaluation
Price range
Day Range
Lowest
914.75
Highest
920.00
52 week range
Lowest
797.05
Highest
1,059.00
Zydus Lifesciences News
Zydus Lifesciences Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Divi's Laboratories
Moderately Bearish
6,314.65-0.341,67,505.9078.2711.470.460.01
Dr Reddy's Laboratories
Bullish
1,275.95-0.241,06,489.6818.803.170.632.34
Torrent Pharmaceuticals
Neutral
3,738.60-0.501,26,742.0066.6416.920.8417.62
Sun Pharmaceutical Industries
Neutral
1,774.75-0.454,25,811.5837.946.040.880.50
Cipla
Bearish
1,493.60-0.431,20,648.7123.333.940.850.81
Mutual Fund Ownership
View all
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
NA
  • Amount Invested (Cr.) 220.96
  • % of AUM 4.01
ICICI Prudential Nifty Pharma Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 2.57
  • % of AUM 3.05
Kotak Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 10.70
  • % of AUM 2.46
Nippon India Nifty Alpha Low Volatility 30 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 33.51
  • % of AUM 2.43
Edelweiss Nifty Alpha Low Volatility 30 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 3.76
  • % of AUM 2.43
Zydus Lifesciences Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-11-06Quarterly Results & Fund raising
2025-08-12Quarterly Results
2025-05-20Audited Results & Final Dividend
2025-02-05Quarterly Results
2024-11-12Quarterly Results
About the company Zydus Lifesciences
  • IndustryBiotechnology & Drugs
  • ISININE010B01027
  • BSE Code532321
  • NSE CodeZYDUSLIFE
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
  • Management Info
  • Tushar ShroffChief Financial Officer
  • Dhaval SoniCompany Secretary, Compliance Officer
  • Sharvil PatelManaging Director, Executive Director
  • Ganesh NayakExecutive Director
Zydus Lifesciences Share Price FAQs

Zydus Lifesciences is trading at 917.20 as on Wed Dec 17 2025 05:52:19. This is 0.36% upper as compared to its previous closing price of 913.90.

The market capitalization of Zydus Lifesciences is 92291.78 Cr as on Wed Dec 17 2025 05:52:19.

The average broker rating on Zydus Lifesciences is Hold. The breakup of analyst rating is given below -

  • 4 analysts have given a strong buy rating
  • 5 analysts have given a buy rating
  • 12 analysts have given a hold rating
  • 5 analysts have given a sell rating
  • 2 analysts have given a strong sell rating

The 52 wk high for Zydus Lifesciences is 1059.00 whereas the 52 wk low is 797.05

Zydus Lifesciences can be analyzed on the following key metrics -

  • TTM P/E: 20.08
  • Sector P/E: 28.46
  • Dividend Yield: 1.20%
  • D/E ratio: 0.38

Zydus Lifesciences reported a net profit of 4525.50 Cr in 2025.

The Mutual Fund Shareholding was 4.70% at the end of 30 Sep 2025.

Quick Links
EQUITY QUICK LINKS
Zydus Lifesciences QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Business News/Market/Market Stats/  Zydus Lifesciences share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.